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Recommended by Jiro Nakamura
Purpose. The objective of this study was to determine the eﬃcacy of dietary supplementation with the metal chelators, trientine
or citric acid, in preventing the development of cardiomyopathy in the Zucker diabetic rat. Hypothesis. We hypothesized that
dietary chelators would attenuate metal-catalyzed oxidative stress and damage in tissues and protect against pathological changes in
ventricular structure and function in type II diabetes. Methods. Animals (10 weeks old) included lean control (LC, fa/+), untreated
Zucker diabetic fatty (ZDF, fa/fa), and ZDF rats treated with either trientine (triethylenetetramine) or citrate at 20 mg/d in drinking
water, starting when rats were frankly diabetic. Cardiac functional assessment was determined using a Millar pressure/volume
catheter placed in the left ventricle at 32 weeks of age. Results. End diastolic volume for the ZDF animals increased by 36%
indicating LV dilatation (P < .05) and was accompanied by a 30% increase in the end diastolic pressure (P ≤ .05). Both
trientine and citric acid prevented the increases in EDV and EDP (P < .05). Ejection fraction and myocardial relaxation were also
significantly improved with chelator treatment. Conclusion. Dietary supplementation with trientine and citric acid significantly
prevented structural and functional changes in the diabetic heart, supporting the merits of mild chelators for prevention of
cardiovascular disease in diabetes.
Copyright © 2009 J. W. Baynes and D. B. Murray. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. Introduction
Cardiovascular disease is the primary cause of increased
mortality in diabetes. Clinically, over 60% of diabetics
succumb to heart failure. Moreover, the 5-year survival rate
following the first documented heart injury is less than
50% [1]. These statistics underscore the importance of
investigating more direct and eﬀective treatment strategies
for the ever increasing diabetic population. Recently, the
transition metal chelator, trientine, was shown to improve
cardiac extracellular matrix remodeling and cardiovascular
function in streptozotocin-induced (type 1) diabetic rats [2].
In clinical studies, trientine administration for 6 months to a
group of patients with type 2 diabetes also led to a decrease
in left ventricular mass toward normal, concomitant with
increased urinary copper excretion [3]. Similar protective
eﬀects on cardiovascular function are seen with breakers of
advanced glycation end-products (AGE breakers) in both
preclinical and clinical studies [4, 5]. However, these com-
pounds and their degradation products are potent chelators,
and there is evidence that chelation of transition metals is the
primary mechanism of action of AGE breakers [6–9]. The
beneficial eﬀects of AGE inhibitors in treatment of diabetic
complications are also attributed, in part, to their chelation
activity and inhibition of oxidative stress [7, 8].
Trientine and AGE breakers and inhibitors are potent
chelators of copper, and to a lesser extent iron, and are
thought to act by inhibition of metal-catalyzed oxidative
stress. Oxidative stress is implicated in the development
of the full range of diabetic complications, including
nephropathy, neuropathy, retinopathy, and micro- and
macrovascular disease [10–13]. Although both enzymatic
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Figure 1: Representative left ventricle pressure/volume loops from
lean control, untreated ZDF, ZDF + trientine, ZDF + Citric Acid
animals. Beat by beat analysis of changes in LV hemodynamic
parameters plotted along pressure (y-axis) and volume (x-axis)
indicates a shift to the right in the ZDF animals suggesting LV
dilatation, which is corrected by both trientine and citric acid.
and nonenzymatic reactions contribute to the increase in
oxidative stress and inflammation in diabetes, nonenzymatic
mechanisms are clearly important, not only directly by
metal-catalyzed production of reactive oxygen species (ROS)
[10, 11, 14], but also through glycoxidation and lipoxidation
reactions [15, 16]. The transition metals, Cu and Fe, have
also been linked to oxidative damage in other organ systems
and diseases [13, 17–19], and in numerous studies, chelators
have provided protection against development of diabetic
complications in animal models of diabetes [17–20].
Accordingly, we designed this study to determine if the
relatively inexpensive and well-tolerated chelators, trientine
and citric acid, would alter the onset of cardiomyopathy in
the Zucker diabetic rat, a model of type II diabetes, which
accounts for more than 90% of the diabetic population.
We show here that both of these mild chelators provide
protection against the development of diabetes induced
cardiomyopathy, supporting the merits of further research
on chelation therapy for prevention and treatment of this
and other diabetic complications.
2. Materials and Methods
2.1. Experimental Design. All protocols were approved by
the Institutional Animal Care and Use Committee of the
University of South Carolina and conform to the Guide
for the Care and Use of Laboratory Animals, published by
the US National Institutes of Health (NIH Publication
no. 85-23, revised 1996). All chemicals and reagents were
purchased from Sigma-Aldrich (St. Louis, Mo, USA), unless
otherwise indicated. All animals were housed two to a cage
in a 12:12 hours dark/light cycle controlled room. Male
Zucker diabetic fatty rats (ZDF fa/fa) and male Zucker lean
control heterozygous litter mates (LC fa/+) were obtained
at 6 weeks of age (∼200 g) from Charles River Laboratories
(Wilmington, Mass, USA). The ZDF is an inbred rat model
of adult onset type II diabetes, characterized by gradual
development of insulin resistance, hyperinsulinemia and
hyperglycemia. All Animals were maintained on Purina 5008
rat chow with water ad libitum. At the age of 10 weeks,
after confirming hyperglycemia by tail vein blood samples
[378 ± 46 mg/dL; mean ± SD], the animals were divided
into four groups: (1) lean control rats (LC; n = 7), (2)
untreated ZDF rats (n = 10), (3) ZDF rats treated with
trientine (ZDF + TN, n = 8) administered in drinking water
(1 g/L) as previously reported [2], and (4) ZDF rats treated
with citric acid (ZDF + CA, n = 4) administered at the same
dose in drinking water (1 g/L). Left ventricular systolic and
diastolic structural and functional parameters were assessed
at 32 weeks of age, just prior to sacrifice. Plasma samples were
collected, the heart and kidneys were removed, rinsed in ice
cold PBS and weighed, and then portions either snap frozen
in liquid nitrogen for biochemical analysis or placed in 4%
paraformaldehyde fixative for histological analysis.
2.2. Left Ventricular Functional Assessment. As previously
described, LV systolic and diastolic pressure and volume
functional analysis were performed in anesthetized rats
using a high-fidelity Millar pressure/volume (SPR-838; Mil-
lar Instruments, Houston, Tex USA) conductance catheter
inserted into the LV via the right carotid artery [21]. Char-
acteristic pressure-volume loops from these experiments are
illustrated in Figure 1. For calibration, this measurement
technique requires that a small amount (0.1 mL) of 15%
saline be introduced into the blood volume of the anes-
thetized animal at the end of the experimental protocol as a
correction factor for the blood-LV tissue interface. Data were
analyzed using PVAN 3.5 Millar Instruments software.
2.3. Statistics. Statistical analyses were performed with
Graphpad 5.0 software (Prism Inc., San Diego, Calif, USA).
All grouped data are expressed as means ± SEM unless
otherwise noted. Grouped data comparisons were made by
one-way analysis of variance with intergroup comparisons
analyzed using Bonferroni’s posthoc testing. Non parametric
Kruskal-Wallis test with Gaussian approximation was uti-
lized to analyze the rank/scoring system of the hydronephro-
sis ratings. Statistical significance was taken to be P ≤ .05.
3. Results
3.1. Comparison of Body and LV Weights between Lean
Control, Untreated ZDF, ZDF + Trientine, and ZDF + Citric
Acid at 32 Weeks of Age. Compared to lean control animals,
there was a significant reduction in whole body and LV
weight in the ZDF and ZDF + CA groups at 32 weeks
of age (Table 1). Body weight and LV weight were, on
average, lower in the trientine treated group, but were not
statistically diﬀerent from LC. LV mass/BW ratios were
similar (Table 1) in all groups. These trends were also evident
when normalized to tibial lengths (data not shown). Mean
arterial blood pressure was not appreciably diﬀerent between
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Table 1: Comparison of body weight, LV weight, and blood glucose in lean control, untreated ZDF, ZDF + trientine, and ZDF + citric acid
at 32 weeks of age. All values are reported as average ± SD. ∗ denotes P ≤ .05 compared to lean control.
Body weight (g) LV weight (mg) LV/body weight index Blood glucose (mg/dL)
Lean control 456± 11 920± 32 2.2 105± 7
ZDF 358± 39∗ 796± 80∗ 2.0 392± 29∗
ZDF + trientine 403± 50 825± 76 2.1 370± 54∗
ZDF + citric acid 327± 17∗ 694± 28∗ 2.1 384± 51∗
Table 2: Comparison of in vivo left ventricular functional parameters in lean control untreated ZDF, ZDF + trientine, and ZDF + citric acid
at 32 weeks of age. Values are presented as mean ± SEM. n = 4–6 per group. ∗ denotes P < .05 versus age-matched lean control. † denotes
P < .05 versus untreated ZDF.
Heart rate
(bpm)
Cardiac output
(mL/min)
Stroke volume
(μL)
End diastolic
pressure
(mmHg)
End systolic
pressure
(mmHg)
Max dP/dt Min dP/dt
Lean control 291± 9 38± 2 121± 5 7± 0.4 132± 7 7244± 332 −7533± 554
ZDF 279± 7 39± 3 150± 9∗ 10± 0.6∗ 135± 7 7423± 500 −6777± 518
ZDF + trientine 270± 12 35± 4 130± 9 7± 0.3† 136± 11 7184± 576 −7392± 376
ZDF + citric acid 248± 13∗ 31± 2 122± 5 7± 0.5† 129± 13 6509± 484 −6659± 707
lean control and ZDF (113 ± 5 versus 108 ± 6 mmHg; LC
versus ZDF), or in the trientine or citric acid treated ZDF
animals (119 ± 9 versus 94 ± 9 mmHg; ZDF + TN versus
ZDF + CA, resp.). Lastly, blood glucose was increased to
a comparable level in all the ZDF groups regardless of
treatment (Table 1).
3.2. Left Ventricle Morphology and Function. Although heart
rate was significantly reduced in the ZDF + CA treated
group compared to LC, no diﬀerences in cardiac output were
evident between any of the groups (Table 2). Stroke volume
was significantly increased in the untreated ZDF group
relative to LC (Table 2), but was not significantly aﬀected by
either chelator. End diastolic pressure (EDP) (Table 2) and
end diastolic volume (EDV) (Figure 2(a)) were significantly
increased in ZDF animals, compared to controls. In contrast,
although end systolic pressure (ESP) was not increased in
ZDF animals (Table 2), there was still a significant increase
in end systolic volume ESV (Figure 2(b)). These increases in
EDP, EDV, and ESV, which are common in type 2 diabetic
patients, were completely prevented by treatment with either
trientine or citric acid (Table 2 and Figure 2).
Neither maximum nor minimum first derivative of LV
pressure (dP/dt) (measurements of myocardial contractility
and ventricular wall stiﬀness, resp.) was statistically diﬀerent
among groups (Table 2). However, compared to LC, the
optimal volume for maximum dP/dt (Vol@dP/dt max) (i.e.,
the volume at which maximal contractility is generated) was
significantly increased in the ZDF group (Figure 3(a)). This
diabetes induced change in Vol@dP/dt max at 32 weeks
of age was prevented in both the ZDF + TN and ZDF +
CA groups (314 ± 33 versus 264 ± 5μL; resp. P ≤ .05
versus ZDF). Likewise the optimal volume for minimum
dP/dt (Vol@dP/dt min) was also significantly increased in
the untreated ZDF group compared to LC (Figure 3(b)).
Changes in Vol@dP/dt min were also prevented by both
trientine and citric acid (207 ± 20 and 186 ± 25μL, resp.;
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Figure 2: Comparison of (a) LV end diastolic volume and (b)
end systolic volume between lean control and Zucker diabetic fatty
(ZDF), ZDF + trientine, and ZDF + citric acid treated rats. Values
are reported as mean ± SEM (n = 4–6 per group). ∗ denotes
P ≤ .05 versus LC. † denotes P ≤ .05 versus ZDF.
P ≤ .05 versus ZDF). Further, ejection fraction which was
34% in the untreated ZDF group was significantly improved,
but not completely corrected by treatment with trientine
(45%) or citric acid (43%). Lastly, in a eﬀort to assess
alterations in passive tissue property reflective of changes
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Figure 3: Evaluation of the LV chamber volumes at which (a)
maximum and (b) minimum rate pressure product is generated
between lean control and Zucker diabetic fatty (ZDF), ZDF +
trientine, and ZDF + citric acid treated rats. Values are reported as
mean ± SEM (n = 4–6 per group). ∗ denotes P ≤ .05 versus LC.
† denotes P ≤ .05 versus ZDF.
in the extracellular matrix, we analyzed the time constant
of LV pressure decay (Tau) according to Weiss et al. [22].
Relative to age-matched LC, Tau, a measurement of the
time needed for LV relaxation, was significantly increased
in the ZDF group (12 ± 0.3 versus 15 ± 0.1 milliseconds,
P ≤ .05). Tau values for ZDF + TN and ZDF + CA were not
significantly diﬀerent from LC, indicating attenuation in the
overall stiﬀening or loss of compliance seen in the ventricle
of the ZDF animals.
4. Discussion
Chelation therapy has a bad reputation in modern medicine.
Indeed, the second citation in a Google search for “chelation
therapy” yields the website “Quackwatch,” and an article
titled: Chelation Therapy: Unproven Claims and Unsound
Theories. However, chelation has proven eﬀective in numer-
ous studies in attenuating microvascular (renal, retinal,
neuronal) as well as cardiovascular complications in animal
models of diabetes [2, 3, 19, 23]. Adverse changes in vascular
and ventricular structural and functional parameters are
a major cause of cardiovascular failure in people with
diabetes. Trientine, a chelator with a low toxicity profile, has
been used therapeutically for many years for treatment of
copper overload [13, 24]. Moreover, altered Cu (and iron)
homeostasis is directly implicated in diabetic complications
[20]. Alterations in iron homeostasis are also reported in dia-
betic subjects [25, 26], and treatment with desferrioxamine
inhibits the development of neuropathy and microvascular
disease in diabetic rats [27, 28]. Preclinical trials have also
shown that short-term metal chelation by oral trientine can
attenuate ventricular changes in diabetic patients [3, 29].
These previous studies demonstrated that trientine increased
urinary copper excretion and also induced significant benefi-
cial changes in left ventricular extracellular matrix structure.
In our studies of cardiac function, the data indicate that
significant changes in LV chamber morphology occurred in
the untreated ZDF animals as a diabetes-induced adaptation
in an attempt to maintain overall function. The two chelators
inhibited adverse changes in LV chamber morphology and
relaxation. Specifically, type II diabetic rats treated with
trientine or citric acid had significantly better in vivo left
ventricular end systolic and end diastolic pressure/volume
parameters than untreated animals, without a significant
eﬀect on blood glucose concentration. Additionally, both
volumes at maximum and minimum dP/dt were significantly
improved by trientine indicating that LV chamber under-
went dilatation in order to maintain contractility. These
results indicate that defective transition metal(s) homeostasis
makes a significant contribution to pathogenic LV chamber
remodeling in type II diabetes and that this cardiovascular
pathology is prevented by chelation therapy. Although the
experiments with citric acid were designed as exploratory
and were limited in scope, they are reported here because,
even in a small number of rats, citric acid had significant
beneficial eﬀects on both cardiac structure and function.
Further studies on the eﬀects of dietary citrate on iron and
copper uptake and excretion in type II diabetes may provide
some insight into the beneficial eﬀects of citrus fruits in the
human diet.
The diﬀerence in LV mass between the age-matched lean
control and the untreated ZDF is an interesting observation.
Indeed, changes in LV mass and or geometry greatly aﬀect
the overall function of the heart. Hypertrophy can be
defined as either concentric (increase in wall thickness of
the LV chamber typically characterized by an increase in
the cross-sectional area of the myocytes due to parallel
addition of sarcomeres) or eccentric (elongation of the LV
chamber characterized by growth along the longitudinal axis
of the myocytes due to in-series addition of sarcomeres).
In either case, this is a progressive response to chronic
physiologic stress such as alterations in cardiac output due
to altered hemodynamic load on the heart [30]. In the
current study, these changes were prevented by chelator
treatment. Recent clinical studies on the correlation of left
ventricular hypertrophy (LVH) and type II diabetes, based
on echocardiography, indicate that there are a significant
number of individuals who do not present with indication(s)
of LVH [31–33]. Rather than viewing the changes in LV
weight in the current study as a reduction in LV mass, we
believe that the untreated ZDF animals are similar to the
clinical condition, presenting with limited or inadequate
hypertrophy at this time point.
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Work by Cooper et al. suggests the beneficial eﬀects
of chelators may be at the extracellular level [2, 3]. In
those studies trientine treatment was able to attenuate Cu-
mediated activation of TGF-β and Smad, which subse-
quently suppressed collagen production, thereby limiting
ECM accumulation common to the streptozotocin diabetic
model. Further, trientine may not only act to sequester
Cu for urinary excretion but also act to balance the
activity or increase the expression of a number of oxidases
(i.e., extracellular superoxide dismutase and semicarbazide
sensitive amine oxidase) [2, 17]. Chelators also limit the
formation of advance glycation endproducts (AGEs) [8, 17,
18, 34, 35]. AGE crosslinks directly aﬀect ECM structure
and function and also secondarily contribute to sustained
activation of the receptor for AGEs (RAGE), leading to
chronic NFkB mediated inflammatory responses, and ulti-
mately to organ dysfunction [36–38]. Advancements in
our understanding of metal-catalyzed oxidation in the
diabetic setting and application of chelation therapy to
inhibit this process may enhance our ability to limit
the progression of cardiovascular disease in diabetes [6–
8].
It should be noted that diabetic cardiomyopathy is
often accompanied by the development of cardiovascular
autonomic dysfunction. Although we were unable to assess
that in this study, Schreihofer et al. [39] investigated the
sympathetic baroreceptor reflexes in juvenile (7 weeks of
age) and adult (13 weeks of age) lean control and obese
(nondiabetic) Zucker rats. Their results indicated that in
adult obese Zucker rats, acute changes in arterial pressure
evoke smaller sympathetic responses compared to those
observed in age matched lean counterparts. Further, barore-
ceptor reflex impairment included regulation of heart rate
and sympathetic vasomotor control. However, a previous
study by Schmidt et al. [40] analyzed the development of
neuronal axonal dystrophy in the obese Zucker rat model 6
to 7 months after the onset of type II diabetes. In contrast
to the streptozotocin induced model of hyperglycemia,
the ZDF rat model of type 2 diabetes failed to develop
the characteristic neuropathologic lesions of neuroaxonal
dystrophy in the superior mesenteric sympathetic ganglia
and ileal mesenteric nerves. Therefore, a limitation of
this study may be the unappreciated eﬀects of chelator
therapy on diabetes induced changes to autonomic func-
tion.
In summary, chelation of transition metals by trien-
tine or citric acid significantly attenuated structural and
functional changes in the heart in the Zucker type 2
diabetic rat. These observations support a previous work
in the streptozotocin-induced type 1 diabetic rat and in
clinical studies, suggesting that transition metal chelation
can attenuate maladaptive cardiovascular remodeling leading
to cardiac dysfunction in diabetes. Thus, a pharmacologic
regimen incorporating Cu (and Fe) chelation is a potentially
beneficial treatment strategy to prevent or attenuate the
progression of cardiomyopathy in diabetes, even in the
presence of chronic hyperglycemia. However, the question
of whether this treatment improves remodeling or inhibits
damage remains uncertain.
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